scholarly journals Duration of protection against Bordetella pertussis infection elicited by whole-cell and acellular vaccine priming in Polish children and adolescents

Vaccine ◽  
2021 ◽  
Author(s):  
Iwona Paradowska-Stankiewicz ◽  
Agnieszka Rumik ◽  
Joanna Bogusz ◽  
Jakub Zbrzeźniak ◽  
Waldemar Rastawicki ◽  
...  
Author(s):  
Samaneh Saedi ◽  
Azadeh Safarchi ◽  
Faranak Tayebzadeh Moghadam ◽  
Siamak Heidarzadeh ◽  
Vajihe Sadat Nikbin ◽  
...  

Background: Bordetella pertussis, a highly contagious respiratory. Notably, the resurgence of pertussis has recently been associated with the lacking production of vaccine virulence factors. This study aimed to screen pertactin (Prn) and filamentous hemagglutinin (Fha) production in Iran with 50 years' whole cell vaccine (WCV) immunization program. Methods: Overall, 130 B. pertussis isolates collected from Pertussis Reference Laboratory of Iran during 2005-2018. Real-time PCR was performed by targeting IS481, ptxP, IS1001 and IS1002 for species confirmation of B. pertussis. Western-blot was used to evaluate the expression of virulence factors (pertactin and filamentous hemagglutinin). Results: All tested B. pertussis isolates expressed Prn and all except two isolates expressed Fha. We have sequenced genomes of these strains and identified differences compared with genome reference B. pertussis Tohama I. Conclusion: Many countries reporting Prn and Fha-deficiency due to acellular vaccine (ACV) pressure. Our results demonstrate in a country with WCV history, Fha-deficient isolates may rise independently. However, Prn-deficient isolates are more under the ACV pressure in B. pertussis isolates. Continues surveillance will provide a better understanding of the effect of WCV on the evolution of the pathogen deficiency.  


Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 647
Author(s):  
Catherine B. Blackwood ◽  
Emel Sen-Kilic ◽  
Dylan T. Boehm ◽  
Jesse M. Hall ◽  
Melinda E. Varney ◽  
...  

Whole cell vaccines are frequently the first generation of vaccines tested for pathogens and can inform the design of subsequent acellular or subunit vaccines. For respiratory pathogens, administration of vaccines at the mucosal surface can facilitate the generation of a localized mucosal immune response. Here, we examined the innate and vaccine-induced immune responses to infection by two respiratory pathogens: Bordetella pertussis and Pseudomonas aeruginosa. In a model of intranasal administration of whole cell vaccines (WCVs) with the adjuvant curdlan, we examined local and systemic immune responses following infection. These studies showed that intranasal vaccination with a WCV led to a reduction of the bacterial burden in the airways of animals infected with the respective pathogen. However, there were unique changes in the cytokines produced, cells recruited, and inflammation at the site of infection. Both mucosal vaccinations induced antibodies that bind the target pathogen, but linear regression and principal component analysis revealed that protection from these pathogens is not solely related to antibody titer. Protection from P. aeruginosa correlated to a reduction in lung weight, blood lymphocytes and neutrophils, and the cytokines IL-6, TNF-α, KC/GRO, and IL-10, and promotion of serum IgG antibodies and the cytokine IFN-γ in the lung. Protection from B. pertussis infection correlated strongly with increased anti-B-pertussis serum IgG antibodies. These findings reveal valuable correlates of protection for mucosal vaccination that can be used for further development of both B. pertussis and P. aeruginosa vaccines.


2021 ◽  
Vol 21 (1) ◽  
pp. 10-19
Author(s):  
I. A. Alekseeva ◽  
O. V. Perelygina ◽  
E. D. Kolyshkina

Some scientific publications contain data suggesting the “return” or “resurgence” of pertussis. Prevention and elimination of pertussis can only be achieved by extensive immunisation of susceptible populations with a highly effective vaccine. The aim of the study was to characterise available whole-cell and acellular pertussis vaccines and to assess the feasibility of improving their quality, for instance, to demonstrate the role of lipooligosaccharide (LOS)—Bordetella pertussis cell wall antigen—in the induction of adaptive immunity. The paper summarises pathogenesis of pertussis, development of post-infection and post-vaccination immunity, and potential ways of improving pertussis vaccines. Improvement of quality of available vaccines can be achieved by reducing reactogenicity of whole-cell pertussis vaccines and enhancing immunogenic activity of acellular pertussis vaccines. One way to reduce reactogenicity of a whole-cell vaccine is to reduce the number of pertussis cells in the vaccine dose, provided that this does not affect the immunogenic activity of the product. Another possible way of reducing reactogenicity is to select vaccine strains based on the LOS endotoxin content. Improvement of acellular vaccine quality involves addressing many issues, such as identification and isolation of new protective antigens. Literature review demonstrated that LOS is a key antigen, because it is involved in the body’s immune response and ensures Th1 and Th17 cell responses to pertussis, which is crucial for protection from B. pertussis bacteria. Considering the evolutionary stability of the LOS structure, this antigen (i.e. its non-toxic oligosaccharide part) can be considered as a candidate for acellular pertussis vaccine.


JCI Insight ◽  
2021 ◽  
Author(s):  
Ricardo da Silva Antunes ◽  
Ferran Soldevila ◽  
Mikhail Pomaznoy ◽  
Mariana Babor ◽  
Jason Bennett ◽  
...  

2019 ◽  
Vol 25 (2) ◽  
pp. 250.e1-250.e7 ◽  
Author(s):  
S. Son ◽  
V. Thamlikitkul ◽  
K. Chokephaibulkit ◽  
J. Perera ◽  
K. Jayatilleke ◽  
...  

2018 ◽  
Author(s):  
Hassib Narchi ◽  
Afaf Alblooshi ◽  
Korstiaan Pater ◽  
Junu Vazhappully George ◽  
Nael Sahhar ◽  
...  

2013 ◽  
Vol 57 (11) ◽  
pp. 1658-1660 ◽  
Author(s):  
P. Andre ◽  
D. R. Johnson ◽  
D. P. Greenberg ◽  
M. D. Decker

Sign in / Sign up

Export Citation Format

Share Document